Therapy Areas
SK Life Science receives FDA approval for investigational new drug application to study SKL27969
14 January 2022 -

SK Life Science Inc., a subsidiary of South Kore-based SK Biopharmaceuticals Co. Ltd, announced on Thursday that it has received US Food and Drug administration (FDA) approval for the investigational new drug (IND) application to study SKL27969 as a potential treatment for advanced solid tumours.

The company is to carry out a Phase 1/2 open-label, non-randomised, multicentre, dose escalation and expansion study aimed at assessing the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SKL27969 in adult patients with solid tumours.

Marc Kamin, MD, chief medical officer at SK life science, said, 'We look forward to learning more about the potential of SKL27969 as a treatment option for a range of advanced solid tumours. We are excited to expand our R&D efforts into discovering potential new therapies for cancer.'